OraVax, Inc.

2 articles about OraVax, Inc.

• Premas Biotech and Oravax Medical to Test Their Triple Antigen Oral Vaccine Candidate Against Omicron Variant of Concern

  12/1/2021

  Premas Biotech announced today that its joint venture Oravax will initiate testing of their oral virus-like particle (VLP) vaccine candidate against Omicron variant of SARS-CoV 2 virus through preclinical, in vitro and challenge studies to assess its efficacy for the new mutant strain.

• 

  COVID-19 Vaccine To Commence Trials in Israel, Oral Version Underway

  7/23/2021

  Oramed Pharmaceuticals said that its majority-owned firm Oravax Medical would be spearheading the project, first in Israel and later in other international clinical locations.